Myomectomy Market Report 2026

The myomectomy market size has grown strongly in recent years. It will grow from $1.62 billion in 2025 to $1.76 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of uterine fibroids, rising awareness of fertility preservation options, growth in gynecological surgical procedures, expansion of hospital surgical infrastructure, availability of advanced laparoscopic tools.

The myomectomy market size is expected to see strong growth in the next few years. It will grow to $2.41 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing adoption of robotic gynecologic surgeries, rising investments in minimally invasive technologies, growing demand for patient-centric treatment options, expansion of specialized women’s health centers, increasing focus on faster post-surgical recovery. Major trends in the forecast period include increasing adoption of minimally invasive surgical techniques, rising use of robotic-assisted myomectomy procedures, growing preference for fertility-preserving treatments, expansion of advanced surgical instrumentation, enhanced focus on precision surgical outcomes.

The increasing prevalence of uterine disorders is expected to drive the growth of the myomectomy market in the coming years. Uterine disorders encompass a variety of medical conditions affecting the uterus, including fibroids, endometriosis, and uterine cancer, which can cause symptoms such as pain, abnormal bleeding, and infertility. This rising prevalence is linked to factors such as greater awareness, delayed childbearing, hormonal imbalances, and lifestyle changes. Myomectomy is employed in the treatment of uterine disorders to surgically remove fibroids, relieving symptoms like pain, heavy bleeding, and reproductive issues while preserving the uterus. For example, in May 2025, the Cancer Council Victoria, an Australia-based government organization, reported that in 2023, 926 women were diagnosed with uterine cancer, with an incidence rate of 22.3 per 100,000 females, representing 2.4% of all cancers diagnosed and 1.2% of all cancer-related deaths in 2023, making uterine cancer the fifth most commonly diagnosed cancer among females in the region that year. Consequently, the growing prevalence of uterine disorders is propelling the growth of the myomectomy market.

The rising demand for minimally invasive techniques is anticipated to drive the growth of the myomectomy market in the coming years. Minimally invasive surgeries involve surgical methods that utilize small incisions or natural body openings to access and treat internal organs, tissues, or structures, aiming to reduce trauma to the patient’s body. These techniques offer medical, financial, and cosmetic advantages that are attractive to both patients and healthcare providers, contributing to their increasing adoption across various medical fields. Occlusion devices are medical instruments used in minimally invasive procedures to block or close blood vessels, ducts, or other pathways within the body. They are commonly applied in interventional cardiology, radiology, and other specialties to address conditions such as aneurysms, abnormal blood flow, or congenital heart defects. For example, in January 2024, Intuitive Surgical, a US-based medical technology firm, reported that approximately 2,286,000 surgical procedures were performed worldwide using its da Vinci surgical systems in 2023, marking a 22% increase compared to 2022. Consequently, the rising demand for minimally invasive techniques is propelling the growth of the myomectomy devices market.

Major companies in the myomectomy market are concentrating on developing advanced solutions, such as next-generation robotic-assisted surgical systems, to address the growing demand for minimally invasive procedures, enhanced surgical precision, and quicker patient recovery. Robotic-assisted systems are sophisticated surgical platforms that improve the surgeon’s capabilities through high-definition 3D visualization, articulating instruments, and precise motion scaling, offering a substantial advantage over conventional open or laparoscopic surgeries. For example, in March 2023, Intuitive Surgical Inc., a U.S.-based medical technology firm, introduced the da Vinci Xi fifth-generation robotic surgical system, an innovative platform designed to support complex gynecological procedures, including myomectomy. The system combines advanced imaging, ergonomically designed controls, and multi-quadrant access, enabling surgeons to perform precise dissections with minimal tissue damage. Its uses include uterine fibroid removal, hysterectomy, and other gynecologic surgeries, delivering patients reduced post-operative pain, shorter hospital stays, and faster recovery.

Major companies operating in the myomectomy market are Medtronic plc, Stryker Corporation, Boston Scientific Corporation, B. Braun Melsungen AG, Olympus Corporation, Intuitive Surgical Inc., Smith & Nephew plc, Hologic Inc., CooperSurgical Inc., Teleflex Incorporated, Karl Storz SE & Co. KG, CONMED Corporation, Richard Wolf GmbH, ERBE Elektromedizin GmbH, LiNA Medical ApS, KLS Martin Group, Aspen Surgical, BOWA Medical, Aesculap AG, Mindray Medical International Limited.

North America was the largest region in the myomectomy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myomectomy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myomectomy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the myomectomy market by increasing costs of imported laparoscopic instruments, robotic surgical systems, energy devices, and specialized surgical consumables. Hospitals and surgical centers in North America and Europe are most affected due to dependence on imported advanced medical devices, while Asia-Pacific faces cost pressures on equipment procurement. These tariffs are raising procedural costs and slowing adoption of advanced surgical technologies. However, they are also encouraging local manufacturing of surgical instruments, regional supplier development, and innovation in cost-optimized gynecological surgical solutions.

The myomectomy market research report is one of a series of new reports that provides myomectomy market statistics, including myomectomy industry global market size, regional shares, competitors with a myomectomy market share, detailed myomectomy market segments, market trends and opportunities, and any further data you may need to thrive in the myomectomy industry. This myomectomy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myomectomy is a surgical procedure aimed at removing uterine fibroids (non-cancerous growths) while preserving the uterus. It helps alleviate symptoms such as heavy bleeding, pain, and pressure caused by fibroids. This procedure can also improve fertility and is commonly recommended for women who wish to maintain their uterus.

The primary types of myomectomy include abdominal myomectomy, hysteroscopic myomectomy, and laparoscopic myomectomy. Abdominal myomectomy involves surgically removing fibroids from the uterus through an incision in the abdomen. This approach is typically selected when fibroids are large or numerous, as it allows direct access to the uterus. Various instruments are utilized, including laparoscopic power morcellators, harmonic scalpels, laparoscopic sealers, and others, and are employed by a range of end users, such as hospitals and clinics, surgical centers, medical device manufacturers, and more.

The myomectomy market consists of revenues earned by entities by providing services such as preoperative evaluation, surgical techniques, anesthesia services, and fertility counseling and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The myomectomy market also includes sales of laparoscopic suturing devices, laparoscopic power morcellators, trocars, and laparoscopes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.